OncoMatch/Clinical Trials/NCT06159478
Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)
Is NCT06159478 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Binimetinib 15 MG for low-grade glioma.
Treatment: Binimetinib 15 MG — This study is an open-label, parallel, 2-cohort, multicenter, investigator-initiated Phase 2 trial to evaluate the efficacy and safety of binimetinib in patients with advanced or recurrent low-grade glioma or pancreatic cancer harboring BRAF fusion/rearrangement.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Pancreatic Cancer
Biomarker criteria
Required: BRAF fusion
BRAF fusion or rearrangement is detected by reimbursed NGS-based cancer gene panel tests, cancer gene panel tests performed under advanced medical treatment, or clinical study (including liquid biopsy).
Required: BRAF rearrangement
BRAF fusion or rearrangement is detected by reimbursed NGS-based cancer gene panel tests, cancer gene panel tests performed under advanced medical treatment, or clinical study (including liquid biopsy).
Disease stage
Grade: 12 (who)
Prior therapy
Must have received: chemotherapy
Having progression after at least one regimen of chemotherapy excluding adjuvant therapy.
Cannot have received: MEK inhibitor (binimetinib)
Prior treatment with MEK inhibitors.
Lab requirements
Blood counts
Absolute neutrophil count >= 1,500/mm3; Platelet count >= 10.0 x 10^4/mm3; Hemoglobin >= 8.0 g/dL
Kidney function
Serum creatinine <= 1.5 mg/dL
Liver function
Total bilirubin <= 1.5 g/dL; AST <= 100 U/L; ALT <= 100 U/L
Cardiac function
Left ventricular ejection fraction >= 50% by echocardiography or MUGA within 28 days before registration; No cardiac effusion, pleural effusion, or ascites requiring treatment; No symptomatic congestive heart failure of NYHA class II-IV or arrhythmia (over grade 2) occurring in less than 6 months before registration; No myocardial infarction or unstable angina occurring in less than 6 months before registration; Corrected QT interval (QTcF) <= 480 ms in ECG performed within 14 days before enrollment.
Left ventricular ejection fraction >= 50% by echocardiography or MUGA (multigated acquisition scan) within 28 days before registration; No cardiac effusion, pleural effusion, or ascites requiring treatment; Laboratory tests within 14 days before registration and the values are within the following range. Patients should not receive administration of G-CSF and/or blood transfusion within 14 days before the blood collection (1) Absolute neutrophil count >= 1.500/mm3 (2) Platelet count >= 10.0 X 10(4))/mm3 (3) Hemoglobin >= 8.0 g/dL (4) Total bilirubin <= 1.5 g/dL (5) Aspartate aminotransferase (AST) <= 100 U/L (6) Alanine aminotransferase (ALT) <= 100 U/L (7) Serum creatinine <= 1.5 mg/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify